← Human Trials & Peer-Reviewed Studies
Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study.
Plain-language guide to PMID 19648387 (2009): placebo-controlled and pilot phase 2 clinical trial of DMSO (dimethyl sulfoxide, non-peptide solvent) in 9 patients.
Key Facts
- PMID
- 19648387
- Journal
- Mayo Clinic proceedings
- Year
- 2009
- Study type
- Clinical Trial, Phase II
- Authors
- Petrou SP et al. (6 authors)
- DOI
- 10.4065/84.8.702
What This Study Did, in Plain Language
What Was Tested
Researchers studied DMSO (dimethyl sulfoxide, non-peptide solvent) in this phase 2 clinical trial publication.
Adverse effects, 24-hour pad weights, episodes of incontinence, postvoid residuals, and scores on the Blaivas-Groutz anti-incontinence scale, Indevus Urgency Severity Scale, Incontinence Impact Questionnaire-short form, and Urogenital Distress Inventory (6 items) questionnaire were recorded at baseline, 1 month, and 3 months after instillation.
Who Took Part
According to the abstract, 9 patients were involved.
The age groups tagged for this paper are adults, older adults and people over 80, women only.
Twenty-five women with medication-resistant, urodynamic-confirmed idiopathic detrusor overactivity were enrolled.
A total of 9 patients were treated in phase 1 of the study.
How the Study Was Run
The researchers set it up as a placebo-controlled and pilot study.
The comparison arm used a placebo, so changes seen with DMSO (dimethyl sulfoxide, non-peptide solvent) could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger DMSO (dimethyl sulfoxide, non-peptide solvent) study would be practical.
What Was Measured
Adverse effects, 24-hour pad weights, episodes of incontinence, postvoid residuals, and scores on the Blaivas-Groutz anti-incontinence scale, Indevus Urgency Severity Scale, Incontinence Impact Questionnaire-short form, and Urogenital Distress Inventory (6 items) questionnaire were recorded at baseline, 1 month, and 3 months after instillation.
The subject headings attached to it are Administration, Intravesical, Analysis of Variance, Botulinum Toxins, Type A, Pilot Projects, Probability, Risk Assessment and Urinary Bladder, Overactive.
What This Means in Plain Language
The paper is a placebo-controlled and pilot study of DMSO (dimethyl sulfoxide, non-peptide solvent) in 9 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2009 (Mayo Clinic proceedings), a journal based in England.
More context: the DMSO (dimethyl sulfoxide, non-peptide solvent) compound page, all human trials.
Our Notes on the Compound
DMSO (dimethyl sulfoxide, non-peptide solvent): A solvent that carries substances through skin and into the blood, described as a free-radical scavenger; not a peptide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.